ArticleTherapeutic advances in gastroenterology2022
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Article in Therapeutic advances in gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis.JAMA network open · 2026Article
- The Proctitis Paradox: Refractory Ulcerative Proctitis Associated With Development of Disease Complications in a Multicenter South Australian Cohort.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Intracolonic Treatment with a Rifamycin SV In Situ Gelling Formulation Ameliorates Macroscopic and Histological Damage in an Acute Rat Model of Oxazolone-Induced Colitis: A Proof-of-Concept Study.Journal of clinical medicine · 2026Article
- Efficacy of Second-Line Advanced Therapy in Patients with Crohn's Disease After Failure of a First Anti-TNF: A Descriptive Analysis.Journal of clinical medicine · 2026Article
- Article
- Tacrolimus therapy for ulcerative colitis: a retrospective study of factors associated with inducing and maintaining remission.BMC gastroenterology · 2026Article
- A decade of clinical data with vedolizumab: the past, present, and future.Therapeutic advances in gastroenterology · 2026Review
- Vedolizumab in inflammatory bowel disease: pharmacokinetics and the role of immunomodulator co-therapy.Therapeutic advances in gastroenterology · 2026Review
- Final results from the vedolizumab extended access program multinational study demonstrate long-term treatment persistence and safety.Therapeutic advances in gastroenterology · 2026Article
- Celastrol ameliorates ulcerative colitis by inhibiting HSP90-mediated necroptosis of intestinal epithelial cells.Frontiers in pharmacology · 2026Article
- Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study.Intestinal research · 2026Article
- Interpreting vedolizumab persistence: lessons from real-world trajectories in ulcerative colitis.Intestinal research · 2026Article
- Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data.BMC gastroenterology · 2025Article
- Temporal Trends in the Use of Biological Agents in Patients with Inflammatory Bowel Disease: Real-World Data from a Tertiary Inflammatory Bowel Disease Greek Center During a 5-Year Period.Journal of clinical medicine · 2025Article
- Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naïve Patients With Ulcerative Colitis.Alimentary pharmacology & therapeutics · 2025Article
- Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions.Therapeutic advances in gastroenterology · 2025Review
- Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases.Alimentary pharmacology & therapeutics · 2025Article
- Development and Validation of a Scoring System to Predict 2-Year Clinical Remission in Ulcerative Colitis Patients on Vedolizumab.Crohn's & colitis 360 · 2025Article
- Article
- Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.Journal of Crohn's & colitis · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The choice between infliximab (IFX) and vedolizumab (VED) as a first-line biological agent in moderate-to-severe ulcerative colitis (UC) can be difficult. Second-line vedolizumab (VED) efficacy may decline following prior infliximab (IFX) treatment failure in UC patients. However, it is not known whether second-line IFX efficacy declines after failure of first-line VED. Aims: We aimed to compare first-line and second-line persistence of IFX and VED, in particular whether second-line IFX persistence declines after failure of first-line VED. Methods: Persistence of IFX and VED was analysed from the Australian Pharmaceutical Benefits Scheme registry data as either first- or second-line treatment in UC. Propensity score matching (1:1) was conducted in the comparison of first-line treatments. Cox proportional hazard regression analysis was used to identify significant predictors and expressed as a hazard ratio (HR and 95% CI). Results: There were 420 subjects with moderate-to-severe UC who received either first-line IFX ( Conclusion: VED had a significantly longer persistence than IFX as first-line biological agent but does not disadvantage second-line IFX use in moderate-to-severe UC. VED after IFX is associated with significantly poorer persistence. VED, therefore, should be considered as the first-line biological agent of choice in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.